EA201401133A1 - PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISTURBANCES, CONNECTED WITH EXCESSIVE WEIGHT OR OBSERVATION (OPTIONS); - Google Patents

PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISTURBANCES, CONNECTED WITH EXCESSIVE WEIGHT OR OBSERVATION (OPTIONS);

Info

Publication number
EA201401133A1
EA201401133A1 EA201401133A EA201401133A EA201401133A1 EA 201401133 A1 EA201401133 A1 EA 201401133A1 EA 201401133 A EA201401133 A EA 201401133A EA 201401133 A EA201401133 A EA 201401133A EA 201401133 A1 EA201401133 A1 EA 201401133A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
treatment
overweight
obesity
disorders associated
Prior art date
Application number
EA201401133A
Other languages
Russian (ru)
Other versions
EA023747B1 (en
Inventor
Павел Вячеславович КОРНЕВ
Original Assignee
Промомед Холдингс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Промомед Холдингс Лимитед filed Critical Промомед Холдингс Лимитед
Priority to EA201401133A priority Critical patent/EA023747B1/en
Publication of EA201401133A1 publication Critical patent/EA201401133A1/en
Publication of EA023747B1 publication Critical patent/EA023747B1/en

Links

Abstract

Предложены композиции и наборы для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, содержащие ингибиторы дипептидилпептидазы IV (ДПП-IV), метформин и сибутрамин или их фармацевтически приемлемые соли в качестве активных компонентов. Изобретение относится также к применению композиций и наборов для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, в том числе при сахарном диабете II типа, и к способу профилактики и лечения нарушений, связанных с избыточным весом или ожирением, в том числе при сахарном диабете II типа. Композиции обладают выраженным синергетическим эффектом, который проявляется в значительном снижении веса и побочных явлений, а также снижении уровня глюкозы в крови при совместном применении в составе композиций вилдаглиптина или саксаглиптина, метформина и сибутрамина при нарушениях, связанных с избыточным весом или ожирением, в том числе при сахарном диабете II типа.Proposed compositions and kits for the prevention and treatment of disorders associated with overweight or obesity, containing inhibitors of dipeptidyl peptidase IV (DPP-IV), metformin and sibutramine or their pharmaceutically acceptable salts as active ingredients. The invention relates also to the use of compositions and kits for the prevention and treatment of disorders associated with overweight or obesity, including diabetes mellitus type II, and to a method for the prevention and treatment of disorders associated with overweight or obesity, including sugar type II diabetes. The compositions have a pronounced synergistic effect, which is manifested in a significant reduction in weight and side effects, as well as a decrease in blood glucose levels when vildagliptin or saxagliptin, metformin and sibutramine are used in combination with overweight or obesity, including type II diabetes.

EA201401133A 2014-11-13 2014-11-13 Pharmaceutical composition for preventing and treating overweight or obesity related disorders (variants), kits (variants), use thereof and method of preventing and treating overweight or obesity related disorders EA023747B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201401133A EA023747B1 (en) 2014-11-13 2014-11-13 Pharmaceutical composition for preventing and treating overweight or obesity related disorders (variants), kits (variants), use thereof and method of preventing and treating overweight or obesity related disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201401133A EA023747B1 (en) 2014-11-13 2014-11-13 Pharmaceutical composition for preventing and treating overweight or obesity related disorders (variants), kits (variants), use thereof and method of preventing and treating overweight or obesity related disorders

Publications (2)

Publication Number Publication Date
EA201401133A1 true EA201401133A1 (en) 2016-02-29
EA023747B1 EA023747B1 (en) 2016-07-29

Family

ID=55404353

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401133A EA023747B1 (en) 2014-11-13 2014-11-13 Pharmaceutical composition for preventing and treating overweight or obesity related disorders (variants), kits (variants), use thereof and method of preventing and treating overweight or obesity related disorders

Country Status (1)

Country Link
EA (1) EA023747B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114028370A (en) * 2021-11-10 2022-02-11 中山大学 Composition with effects of preventing and treating obesity and related diseases and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
DK2498758T3 (en) * 2009-11-13 2018-10-15 Astrazeneca Ab TWO-LAYER TABLET FORMULATIONS
EP2498757A1 (en) * 2009-11-13 2012-09-19 Bristol-Myers Squibb Company Reduced mass metformin formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114028370A (en) * 2021-11-10 2022-02-11 中山大学 Composition with effects of preventing and treating obesity and related diseases and application thereof
CN114028370B (en) * 2021-11-10 2023-10-24 中山大学 Composition with effects of preventing and treating obesity and related diseases and application thereof

Also Published As

Publication number Publication date
EA023747B1 (en) 2016-07-29

Similar Documents

Publication Publication Date Title
MX2019000586A (en) Treatment of amd using aav sflt-1.
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
EA201490377A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKVINIMODE AND GLATIRAMER ACETATE
EA201491773A1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKININIMODE AND DIMETYL FUMARATE
EA201391033A1 (en) BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
EA201100440A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF THEIR APPLICATION FOR CORRECTION OF URIC ACID LEVEL
PH12017500453B1 (en) Spirocyclic inhibitors of cathepsin c
BR112013029256A2 (en) "Pharmaceutical combinations for use in the treatment of patients with type 2 diabetes, treatment method, and uses of lixisenatide and metformin."
EA201390984A1 (en) HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
MY165122A (en) Dipeptidyl peptidase-iv (dppiv) inhibitory peptide compound, composition containing the same, and production method for the same
MX2017004772A (en) Compositions and methods for physiological delivery using cannabidiol.
AR091724A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION
MX2011012310A (en) Treatment of heart failure with normal ejection fraction.
EA201490516A1 (en) BIFENILKARBOXYAMIDES AS ROCK KINAZ INHIBITORS
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MA32416B1 (en) SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYMETHYL-AND 7-SULFONYLMETHYL-INDOLES AND THEIR USE
EA201401133A1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DISTURBANCES, CONNECTED WITH EXCESSIVE WEIGHT OR OBSERVATION (OPTIONS);
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
IN2014DN09240A (en)
NZ702666A (en) A method of weight reduction
UY36354A (en) AROMATIC COMPOUNDS REPLACED AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES
BR112015020566A2 (en) ror gamma modulators
EA201301352A1 (en) Pharmaceutical compositions and kits for preventing and treating disorders associated with being overweight or obese, their use and method for prophylaxis and treatment of disorders associated with being overweight or obese
WO2013100660A3 (en) Pharmaceutical composition for treatment of eye pain, containing pge2 synthesis inhibitor
IN2014MU00187A (en)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ RU